Alumis (ALMS) Income towards Parent Company (2023 - 2026)
Alumis (ALMS) posted quarterly Income towards Parent Company of -$92.9 million for Q4 2025, down 181.75% year-over-year from $113.6 million in Q4 2024, and up 16.13% quarter-over-quarter from -$110.8 million in Q3 2025.
Alumis (ALMS) Income towards Parent Company (2023 - 2026) Analysis & Trends
Alumis (ALMS) has reported Income towards Parent Company for 3 consecutive years, with -$92.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Income towards Parent Company fell 181.75% year-over-year to -$92.9 million; the TTM figure through Dec 2025 stood at -$250.9 million (down 8.38% YoY), while the FY2025 annual figure was -$243.3 million, down 4.66% from the prior year.
- Income towards Parent Company improved to -$92.9 million in Q4 2025 per ALMS's latest filing, from -$110.8 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $59.3 million in Q2 2025 and bottomed at -$110.8 million in Q3 2025.
- Historically, Income towards Parent Company has averaged -$55.0 million across 3 years, with a median of -$48.9 million in 2024.
- On a YoY basis, Income towards Parent Company climbed as much as 204.98% in 2025 and fell as far as 181.75% in 2025.
- Alumis' Income towards Parent Company stood at -$41.3 million in 2023, then climbed by 20.16% to -$33.0 million in 2024, then sank by 181.75% to -$92.9 million in 2025.
- Business Quant data shows ALMS's Income towards Parent Company at -$92.9 million in Q4 2025, -$110.8 million in Q3 2025, and $59.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Alumis | 3.25 Bn | 2.75 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -142.18 Mn |
| Dec 31, 2025 | -92.89 Mn |
| Sep 30, 2025 | -110.75 Mn |
| Jun 30, 2025 | 59.32 Mn |
| Mar 31, 2025 | -106.62 Mn |
| Dec 31, 2024 | -32.97 Mn |
| Sep 30, 2024 | -93.12 Mn |
| Jun 30, 2024 | -56.51 Mn |
| Mar 31, 2024 | -48.94 Mn |
| Dec 31, 2023 | -41.30 Mn |
| Sep 30, 2023 | -44.56 Mn |
| Jun 30, 2023 | -36.71 Mn |